文献速递泌尿男性生殖肿瘤

177Lu-Lu-PSMA-617对比卡巴他赛治疗转移性去势抵抗性前列腺癌的总生存(TheraP):随机开放标签2期试验的次要结局

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2023-11-30

TheraP研究在澳大利亚11个中心纳入200例多西他赛进展后的转移性去势抵抗性前列腺癌患者,随机接受177Lu-Lu-PSMA-617或卡巴他赛治疗。中位随访35.7个月时,两组总生存相似(限制性平均生存时间19.1个月 vs 19.6个月,差异-0.5个月,p=0.77)。结果支持177Lu-Lu-PSMA-617作为卡巴他赛的替代选择。

要点

  • 177Lu-Lu-PSMA-617组与卡巴他赛组总生存相似,限制性平均生存时间差异-0.5个月(95%CI -3.7至2.7),p=0.77。
  • 因低PSMA表达或2-FDG不一致疾病被排除的61例可随访患者,限制性平均生存时间为11.0个月(95%CI 9.0至13.1)。
  • 延长随访未发现新的安全性信号。

核心结论

  • 结果支持177Lu-Lu-PSMA-617作为多西他赛进展后PSMA阳性转移性去势抵抗性前列腺癌患者卡巴他赛的替代选择。
  • 未发现随机分组间总生存存在差异的证据。
  • 因低PSMA表达或2-FDG不一致疾病被排除的男性中位总生存更短。

研究设计与样本

  • TheraP为开放标签、随机2期试验,在澳大利亚11个中心开展。
  • 291例患者于2018年2月6日至2019年9月3日登记,经研究影像后200例合格并随机1:1接受177Lu-Lu-PSMA-617(n=99)或卡巴他赛(n=101)。
  • 177Lu-Lu-PSMA-617每6周一次,最多6周期,起始8.5 GBq,第6周期降至6.0 GBq;卡巴他赛20 mg/m2每3周一次,最多10周期。
  • 总生存按意向治疗分析,以限制性平均生存时间(RMST)汇总,限制时间36个月,对应中位随访时间。

主要发现

  • 中位随访35.7个月(IQR 31.1至39.2)时,177Lu-Lu-PSMA-617组77例(78%)死亡,卡巴他赛组70例(69%)死亡。
  • 177Lu-Lu-PSMA-617组与卡巴他赛组总生存相似:RMST 19.1个月(95%CI 16.9至21.4)vs 19.6个月(95%CI 17.4至21.8),差异-0.5个月(95%CI -3.7至2.7),p=0.77。
  • 完成研究治疗后,卡巴他赛组20例(20%)和177Lu-Lu-PSMA-617组32例(32%)后续接受了替代方案治疗。
  • 291例登记患者中80例(27%)在初始资格筛查后经68Ga-Ga-PSMA-11和2-FDG PET排除;其中61例有随访资料者RMST为11.0个月(95%CI 9.0至13.1)。
  • 延长随访未发现新的安全性信号。

临床怎么用

  • 作者认为,结果支持177Lu-Lu-PSMA-617作为多西他赛进展后PSMA阳性转移性去势抵抗性前列腺癌患者卡巴他赛的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The TheraP study reported improved prostate-specific antigen responses with lutetium-177 [177Lu]Lu-PSMA-617 versus cabazitaxel in men with metastatic castration-resistant prostate cancer progressing after docetaxel. In this Article, we report the secondary outcome of overall survival with mature follow-up, and an updated imaging biomarker analysis. We also report the outcomes of participants excluded due to ineligibility on gallium-68 [68Ga]Ga-PSMA-11 and 2-[18F]fluoro-2-deoxy-D-glucose (2-[18F]FDG) PET-CT. METHODS: TheraP was an open-label, randomised phase 2 trial at 11 centres in Australia. Eligible participants had metastatic castration-resistant prostate cancer progressing after docetaxel, and PET imaging with [68Ga]Ga-PSMA-11 and 2-[18F]FDG that showed prostate-specific membrane antigen (PSMA)-positive disease and no sites of metastatic disease with discordant 2-[18F]FDG-positive and PSMA-negative findings. Participants were randomly assigned (1:1) to treatment with [177Lu]Lu-PSMA-617 (every 6 weeks for a maximum of six cycles; starting at 8·5 GBq, decreasing by 0.5 GBq to 6·0 GBq for the sixth cycle) versus cabazitaxel (20 mg/m2 every 3 weeks, maximum of ten cycles). Overall survival was analysed by intention-to-treat and summarised as restricted mean survival time (RMST) to account for non-proportional hazards, with a 36-month restriction time corresponding to median follow-up. This trial is registered with ClinicalTrials.gov, NCT03392428, and is complete. FINDINGS: 291 men were registered from Feb 6, 2018, to Sept 3, 2019; after study imaging, 200 were eligible and randomly assigned to treatment with [177Lu]Lu-PSMA-617 (n=99) or cabazitaxel (n=101). After completing study treatment, 20 (20%) participants assigned to cabazitaxel and 32 (32%) assigned to [177Lu]Lu-PSMA-617 were subsequently treated with the alternative regimen. After a median follow-up of 35·7 months (IQR 31·1 to 39·2), 77 (78%) participants had died in the [177Lu]Lu-PSMA-617 group and 70 (69%) participants had died in the cabazitaxel group. Overall survival was similar among those assigned to [177Lu]Lu-PSMA-617 versus those assigned to cabazitaxel (RMST 19·1 months [95% CI 16·9 to 21·4] vs 19·6 months [17·4 to 21·8]; difference -0·5 months [95% CI -3·7 to 2·7]; p=0·77). No additional safety signals were identified with the longer follow-up in this analysis. 80 (27%) of 291 men who were registered after initial eligibility screening were excluded after [68Ga]Ga-PSMA-11 and 2-[18F]FDG PET. In the 61 of these men with follow-up available, RMST was 11·0 months (95% CI 9·0 to 13·1). INTERPRETATION: These results support the use of [177Lu]Lu-PSMA-617 as an alternative to cabazitaxel for PSMA-positive metastatic castration-resistant prostate cancer progressing after docetaxel. We did not find evidence that overall survival differed between the randomised groups. Median overall survival was shorter for men who were excluded because of low PSMA expression or 2-[18F]FDG-discordant disease. FUNDING: Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Prostate Cancer Foundation of Australia, Endocyte (a Novartis company), Australian Nuclear Science and Technology Organization, Movember, It's a Bloke Thing, CAN4CANCER, and The Distinguished Gentleman's Ride.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Hofman MS, Emmett L, Sandhu S, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2023. PMID: 38043558. doi:10.1016/S1470-2045(23)00529-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。